7500 Background: Increased selectivity of the Bruton tyrosine kinase inhibitor (BTKi) acalabrutinib (Aca) vs ibrutinib (Ib) may improve tolerability. We conducted an open-label, randomized, noninferiority, phase 3 trial to compare Aca vs Ib in patients (pts) with chronic lymphocytic leukemia (...
2021SOHO abstract: CLL-115 First Results of a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia 责任编辑 | 书女 声明 本资讯旨在帮助医疗卫生专业人士更好地了解相关疾病领域...
阿可替尼Acalabrutinib与伊布替尼Ibrutinib在慢性淋巴细胞白血病细胞中的比较 伊布替尼通过与酶中的Cys-481残基不可逆结合来抑制布鲁顿酪氨酸激酶(BTK)。然而,它不仅仅作用于BTK,还会抑制其他几种酶,这些酶都含有与BTK中Cys-481同源的半胱氨酸残基。对于复发/难治性或既往未经治疗的慢性淋巴细胞白血病(CLL)患者,伊布...
综上所述,阿可替尼Acalabrutinib对于大多数不耐受伊布替尼Ibrutinib的复发/难治性CLL患者而言,不仅有效且耐受性良好。因此,阿可替尼Acalabrutinib有望成为那些可能从BTK抑制剂治疗中获益但对伊布替尼Ibrutinib不耐受患者的替代治疗选择。 阿可替尼仿制药已在孟加拉上市,如需购药,可出国就医。海得康专注正规海外医疗,...
In a head-to-head comparison in the same biochemical assay, ibrutinib (compound 2) had a potency (as measured by IC50) of 1.5 nM, whereas the potency of spebrutinib (compound 3) was 2.3 nM (Fig. 2). However, the inhibitory potential of spebrutinib was lower in BCR-mediated cell ...
Obviously, this is not head-to-head against ibrutinib. I’m not aware that there is any data showing that you can get response with acalabrutinib in patients who have failed ibrutinib. One of the advantages, besides being more specific in terms of target and having less of a targeted effe...
Paolo Ghia, MD, PhD, reviews data from the ELEVATE-RR trial investigating acalabrutinib versus ibrutinib for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL).
The recent availability of head-to-head trial results can help differentiate the safety and efficacy among BTK inhibi- tors. The phase 3 ELEVATE-RR study compared acalabru- tinib versus ibrutinib in patients with R/R CLL and demon- strated comparable PFS but significantly lower frequency of ...
In a head-to-head trial of Bruton's tyrosine kinase inhibitors, acalabrutinib (Calquence) demonstrated similar efficacy to ibrutinib (Imbruvica), but with less cardiotoxicity, in patients with previously treated chronic lymphocytic leukemia (CLL), a researcher reported. ...
Within the field, there has been a lot of controversy as to whether or not adding obinutuzumab to the [Bruton tyrosine kinase (BTK)] inhibitor and prior studies with rituximab [Rituxan] and ibrutinib [Imbruvica], and other studies kind of turned people off of the idea. This study, however...